

Gallstone Pancreatitis: A Review

Daniel Cucher, MD^a, Narong Kulvatunyou, MD^b,
Donald J. Green, MD^b, Tun Jie, MD^c, Evan S. Ong, MD^{c,*}

KEYWORDS

- Gallstone pancreatitis • Biliary acute pancreatitis • Diagnosis • Management
- Early cholecystectomy

KEY POINTS

- Gallstone disease is the most common cause of acute pancreatitis in the Western world.
- The diagnosis of gallstone pancreatitis (GSP) is based on physical examination, with elevated serum pancreatic enzymes and imaging of biliary tract stones, in the absence of any other compelling etiology.
- The purpose of imaging in GSP is to detect the cause of the disease, identify complications, and gauge severity.
- Severity stratification is essential to ensure that appropriate supportive care and interventions are provided in moderate to severe cases while also not delaying care for patients with mild disease.
- The goal of cholecystectomy is to prevent recurrent GSP.
- Cholecystectomy within 48 hours of admission for mild GSP is safe and feasible.
- Patients with moderate to severe GSP and peripancreatic fluid collections should undergo delayed cholecystectomy to prevent serious infectious complications.
- Endoscopic retrograde cholangiopancreatography and laparoscopic explorations of the common bile duct are effective means of managing concomitant choledocholithiasis.

INTRODUCTION

Gallstone disease is the most common cause of acute pancreatitis in the Western world.^{1–4} In most cases, gallstone pancreatitis (GSP) is a mild and self-limiting disease, and patients may proceed without complications to cholecystectomy to prevent future recurrence. Severe disease occurs in about 20% of cases and is associated

Disclosure: None.

^a Department of Surgery, College of Medicine, University of Arizona, PO Box 245005, Tucson, AZ 85724, USA; ^b Division of Acute Care Surgery, Department of Surgery, Arizona Health Sciences Center, University of Arizona, 1501 North Campbell Avenue, PO Box 245063, Tucson, AZ 85724-5063, USA; ^c Division of Hepatobiliary Surgery, Department of Surgery, Arizona Health Sciences Center, University of Arizona, 1501 North Campbell Avenue, PO Box 245066, Tucson, AZ 85724, USA

* Corresponding author.

E-mail address: eong@surgery.arizona.edu

Surg Clin N Am 94 (2014) 257–280

<http://dx.doi.org/10.1016/j.suc.2014.01.006>

surgical.theclinics.com

0039-6109/14/\$ – see front matter © 2014 Elsevier Inc. All rights reserved.

with significant mortality, and meticulous management is critical. A thorough understanding of the disease process, diagnosis, severity stratification, and principles of management is essential to the appropriate care of patients presenting with this common disease. This article reviews these topics with a focus on surgical management, including the appropriate timing and choice of interventions.

EPIDEMIOLOGY

GSP is most common among women older than 60 years, and the number of cases reported annually is increasing worldwide, possibly as a result of the worsening obesity epidemic.^{1,5} The incidence of acute pancreatitis is estimated at 40 per 100,000 people, and 40% to 50% of cases are biliary in etiology. The burden of acute pancreatitis from all causes in the United States exceeds \$2.2 billion per year, with more than 300,000 inpatient admissions and 20,000 deaths annually.⁶⁻⁸

The prevalence of gallstone disease in the United States and Europe is 10% to 15%, and risk factors for GSP are similar to those for gallstone formation: age, gender, obesity, pregnancy, genetics and family history, fasting and rapid weight loss, and gallbladder stasis, among others.^{9,10} Although symptomatic gallstones most commonly present as biliary colic and acute cholecystitis, the incidence of developing GSP is 3% to 8%, and symptomatic gallstones carry an annual risk for developing GSP of 0.04% to 1.5%.¹¹⁻¹⁴ Once gallstones are implicated in acute pancreatitis, the disease follows a mild course in 80% of patients, and mortality is 1% to 3%. However, in 20% of patients the acute pancreatitis is severe, and mortality approaches 30%.¹⁵

PATHOPHYSIOLOGY

Gallstones have been detected in the feces of up to 90% of patients with GSP, suggesting that the causative stones usually pass into the duodenum spontaneously. The composition of these stones is primarily cholesterol, bile salts, and phospholipids.^{16,17} When bile becomes supersaturated, overabundant cholesterol precipitates as crystals, which mix with bilirubin and solidify to form biliary sludge, which may then aggregate to form gallstones.¹⁸ Although gallstone migration into the common bile duct (CBD) may be a relatively common event, the stones cause GSP with far less regularity.¹⁹

Bernard and Prince first described the relationship of gallstones and acute pancreatitis in 1852 and 1882, followed by Opie in 1901.^{4,20-22} There is an impressive body of basic science research focused on the intricacies of this relationship and the exact mechanism by which gallstones cause acute pancreatitis. Risk factors include multiple small stones less than 0.5 mm in size, and a large cystic duct.²³⁻²⁵ Multiple theories have been proposed to describe how gallstones set off the inflammatory response in acute pancreatitis, and a commonly accepted mechanism involves a transient obstruction of the bile or pancreatic duct by an impacted or passing stone. Alternatively, biliary sludge may cause cholestasis or irritate the sphincter of Oddi, causing edema and biliopancreatic outflow obstruction. This process initiates an intracellular activation of digestive enzymes within the pancreas, but the mechanism is not well understood. Biliopancreatic reflux resulting from increased ductal pressure may contribute, but this theory has been challenged based on physiologic studies demonstrating a higher secretory pressure in the pancreatic duct than in the bile duct. In addition, some researchers have observed that sterile bile under physiologic pressures is not harmful to the pancreas, although this has also been challenged.^{26,27} Nevertheless, increased intraductal pressure likely plays a role, because the extent of

pancreatic injury is related to the duration of ampullary obstruction.^{28,29} The pancreatic sphincter, exocrine secretions, mucosal barrier, and the delayed activation of trypsinogen in the duodenum are all protective elements of normal biliopancreatic physiology. In GSP, this homeostasis is altered and pancreatic injury is compounded by inflammatory cytokines, which may worsen pancreatic parenchymal damage and potentially incite the systemic inflammatory response syndrome (SIRS).

DIAGNOSIS

History and Physical Examination

Most patients presenting with GSP complain of typical symptoms of pancreatitis, and fewer may also provide a history of biliary colic. The most common complaint is sudden-onset epigastric or right upper quadrant abdominal pain that is unrelenting, and in 50% of cases radiates to the back.¹⁰ Associated symptoms are nausea and vomiting. A strong history of alcohol abuse should raise a suspicion of alcoholic pancreatitis.³⁰ Physical examination usually demonstrates impressive abdominal tenderness, and patients with severe pancreatitis may also exhibit signs suggestive of an acute surgical abdomen. Immediate evaluation is necessary in patients with peritoneal findings, because the presentation of severe acute pancreatitis may mimic intestinal perforation. As with acute cholecystitis, the pain is exacerbated by eating or drinking. Peripancreatic inflammation may result in a generalized ileus, which causes hypoactive bowel sounds and anorexia. Patients with moderate to severe disease may also present with symptoms of SIRS, including pyrexia, tachycardia, and tachypnea.

Laboratory Evaluation

Laboratory analysis is indispensable in the initial diagnosis of acute pancreatitis. Upper abdominal pain with amylase or lipase 3-times the upper normal limit is diagnostic of acute pancreatitis in many cases, and the addition of cholelithiasis on imaging may sufficiently identify the cause as biliary. Lipase is highly sensitive (>90%) in acute pancreatitis and also has an advantage over amylase in specificity, because lipase is produced primarily by pancreatic acinar cells, whereas amylase is also found in saliva. The level of amylase typically increases within 2 to 12 hours after onset and normalizes within 3 to 5 days, whereas lipase peaks at 24 hours and may stay elevated for several days.³¹ Of importance, the degree of elevation of amylase and lipase do not correlate with disease severity.³² Despite this limitation, higher levels of amylase have been observed in gallstone pancreatitis in comparison with alcoholic pancreatitis.³³

A complete blood count is likely to show leukocytosis. It has also been observed that hematocrit correlates modestly with disease severity.¹⁵ A basic metabolic panel is useful in detecting metabolic derangements, and may also demonstrate mild hyperglycemia from decreased insulin secretion and increased glucagon.⁷ Renal function is also important to consider in severe disease where organ failure is a potential sequela. In addition, patients with acute pancreatitis of any origin may present as hypovolemic, with acute kidney injury correctable by adequate volume resuscitation. Bicarbonate levels are also a marker of resuscitation and can correlate with disease severity (see [Indices of Severity](#) in the section Management).

Liver function tests are also essential in the initial evaluation. Because the underlying pathology in GSP may involve a biliary obstruction, albeit transitory in most cases, patients may present with elevated bilirubin and transaminases. Transaminases are usually only modestly elevated, unlike the high levels seen in viral hepatitis. However, in cases where a stone is impacted they may increase markedly, but normalize after

resolution within days as opposed to weeks. Except in sustained choledocholithiasis, the bilirubin level is usually less than 15 mg/dL, because the obstruction is generally incomplete or intermittent.³⁴ In 10% of cases of GSP, liver function tests (LFTs) are normal.³⁵ Although poorly sensitive (48%), an alanine aminotransferase level more than 3 times the upper limit within 24 to 48 hours of onset is the best predictor of GSP, with a positive predictive value of 95%.³⁶ In addition, alkaline phosphatase and γ -glutamyl transpeptidase may be elevated, particularly if cholestasis persists.

Initial laboratory workup for acute pancreatitis should also include triglyceride and calcium levels for the consideration of hypertriglyceridemia and hypercalcemia as possible etiologic factors. In idiopathic pancreatitis, immunoglobulin G4 may help to identify autoimmune pancreatitis.

Imaging

The purpose of imaging in acute pancreatitis is 3-fold: to detect the cause of the disease (biliary stones, neoplasms, anatomic variances), to identify complications (fluid collections, pseudocysts, hemorrhage), and to gauge the severity of the disease (peripancreatic inflammation, pancreatic necrosis).

Ultrasonography

Every patient presenting with acute pancreatitis and no obvious alternative cause should undergo transabdominal ultrasonography to isolate gallstones as the possible cause. Ultrasonography is inexpensive, sensitive, and widely available. In the past decade the technology has evolved, allowing for portable ultrasound devices with vastly improved resolution. Ultrasonography spares patients the pain of an invasive test and the ionizing radiation of computed tomography (CT). Of note, ultrasonography studies are obtained by trained technicians and are operator dependent.

In general, the presence of cholelithiasis or sludge on ultrasonography (Fig. 1), in the absence of other likely causes, is sufficient evidence to diagnose GSP when combined with a typical presentation and elevated pancreatic enzymes. Ultrasonography is 95% sensitive for cholelithiasis, but in GSP, overlying bowel gas attributable to ileus may decrease sensitivity to 60% to 80%.^{32,37} In the detection of choledocholithiasis, ultrasonography is reported to be 25% to 60% sensitive.^{38–40} Ultrasonography is useful in detecting dilated intrahepatic and extrahepatic bile ducts, which may indicate obstruction, but is less sensitive in the context of GSP because the obstruction is




Fig. 1. Typical ultrasonogram illustrating cholelithiasis and gallbladder sludge.

acute. Ultrasonography may also fail to detect stones smaller than 4 mm, and small stones are a known risk factor for GSP.⁴¹ Despite its limitations, ultrasonography remains the standard imaging study in the diagnosis of GSP, and in imaging terms is sufficient for most patients with mild disease.

Computed tomography

The utility of CT in GSP is to detect the anatomic changes that correlate with complications and mortality.⁴² CT is often not an essential study in mild GSP, but provides more useful information in moderate to severe cases. CT is 85% to 97% sensitive and 88% to 96% specific for common duct stones when contrast is used (Fig. 2).^{43–45} The use of CT for stratification of severity and to direct management requires appropriate timing and technique. Pancreatic necrosis is best visualized on CT at 2 to 3 days after the onset of symptoms.⁴⁶ If an initial CT was obtained during diagnosis, it may need to be repeated at 3 days if the patient's pain is severe and persistent, and laboratory values fail to trend toward normal. To optimize radiographic evaluation of the pancreas, a pancreatic protocol should be specified, comprising 2- to 3-mm cuts through the pancreas, intravenous contrast, and both pancreatic and venous phases of imaging. Oral contrast should be avoided, as it causes artifact in the duodenum that limits the study. The Balthazar CT severity index was developed to help stratify patients with acute pancreatitis (see [Indices of Severity](#) in the section Management).

Magnetic resonance imaging

To understand the role of magnetic resonance imaging (MRI), it is important to differentiate between abdominal MRI and magnetic resonance cholangiopancreatography (MRCP). Whereas abdominal MRI refers to series of images of the abdomen, MRCP describes a specific protocol designed to enhance fluid within the biliary system. It is a noninvasive imaging technique that serves diagnostic aims similar to those of endoscopic retrograde cholangiopancreatography (ERCP) with comparable accuracy. MRCP produces images that clearly define the biliary and pancreatic duct anatomy to delineate anatomic abnormalities, such as pancreas divisum, a disruption of the pancreatic duct, or filling defects that may represent tumors or gallstones. MRCP is reported to be 85% to 90% sensitive in detecting CBD stones, with 93%



Fig. 2. Computed tomography scan demonstrating peripancreatic inflammatory changes and an obstructing stone (*arrow*) in a dilated distal common bile duct (CBD).

to 95% specificity.^{47,48} An advantage of MRCP is the ability to detect stones as small as 2 mm, although this modality still has limited sensitivity for most stones smaller than 5 mm. MRCP is likely to confirm choledocholithiasis, and is commonly used by clinicians to help select patients for ERCP.

Although more expensive and less available than CT, MRI is excellent at visualizing choledocholithiasis, and is particularly useful in evaluating the complications of GSP. MRI is capable of distinguishing pancreatic fluid collections from liquefied necrosis, and is also helpful in diagnosing pancreatic hemorrhage (**Fig. 3**).^{10,49} The effective use of MRI relies heavily on updated technology and experts in radiology who are facile at interpreting the data.

Endoscopic ultrasonography

Endoscopic ultrasonography (EUS) is a diagnostic modality with substantial utility in diagnosing hepatobiliary abnormalities. It is performed by advancing a specialized endoscopic ultrasound probe into the upper gastrointestinal tract. The close proximity to biliopancreatic structures allows for visualization superior to that of transabdominal ultrasonography. Diagnostically, EUS is 93% to 98% sensitive and 97% to 100% specific for choledocholithiasis.^{47,50} It has a negative predictive value of 93% to 100%, and may spare patients without common duct stones unnecessary ERCP.^{51–53} EUS has also been used to exclude choledocholithiasis in pregnant patients with GSP, and in patients who have contraindications to MRCP such as implanted metallic devices. The safety profile of EUS is superior to diagnostic ERCP, and its use in the pretherapeutic ERCP setting has been strongly advocated.⁵¹

MANAGEMENT

A central principle in determining the best course of management is predicting the severity of the disease. GSP is a disease with a broad spectrum of severity, ranging from mild pancreatic inflammation that resolves within 24 hours to fulminant infected pancreatic necrosis. Self-limited pancreatitis has a mortality of 1% to 3%, and describes 80% of cases. In 15% to 25% of patients with all forms of acute pancreatitis the disease may progress to pancreatic necrosis, and some of these patients will progress further to infected pancreatic necrosis with a mortality of 30%.¹⁵ It is therefore essential to determine the severity of the disease early in the hospital course to ensure that appropriate supportive care and interventions are provided while also




Fig. 3. Precontrast T1-weighted magnetic resonance image demonstrating severe hemorrhagic pancreatitis as extensive pancreatic enhancement.

not delaying care for patients with mild disease. Several models have been developed to assist in risk stratification and predict mortality in patients presenting with acute pancreatitis.

Indices of Severity

The Ranson score is still among the most widely used severity indices in the United States, and is calculated based on 11 parameters at the time of admission and at 48 hours. A modification of this index specifically for biliary pancreatitis uses 10 parameters, and reflects a different threshold (Table 1). A Ranson score of 3 or greater classifies a patient with severe disease. The positive predictive value has been reported to range from 37% to 70%, and one study demonstrated that the predictive power of the Ranson criteria is similar to good clinical judgment.^{56–59}

The APACHE-II score was developed to predict mortality in patients in the intensive care unit (ICU), and has been widely applied to patients with acute pancreatitis (Box 1). APACHE-II at 48 hours is reported to have a higher positive predictive value than the Ranson score.⁵⁶ In addition, the APACHE-II score may be calculated at any time during admission, and an increase or decrease in this score has been found to correlate with clinical improvement or deterioration.^{60,61} An APACHE-II score of 8 or greater indicates severe disease.

The bedside index for severity in acute pancreatitis (BISAP) is based on 5 parameters, 1 of which is the presence of SIRS. A score of 3 or greater is associated with higher mortality, and is reported to have accuracy similar to that of the Ranson and APACHE-II scores.⁵⁷

The revised Atlanta Classification of acute pancreatitis (2012) is a means of categorizing the severity of acute pancreatitis based on clinical and radiographic data. It describes an early phase, which defines the early local and systemic responses to pancreatic injury, and a late phase of acute pancreatitis, which is limited to moderate and severe pancreatitis. The classification is divided into mild, moderate, and severe pancreatitis based on the presence of local and systemic complications, and the

Parameter	All Causes of Pancreatitis	Gallstone Pancreatitis
On Admission		
Age	>55	>70
White blood cell count	>16,000	>18,000
Serum glucose (mg/dL)	>200	>220
Serum AST (IU/L)	>250	>250
Serum LDH (IU/L)	>350	>400
Within 48 h		
Base deficit (mmol/L)	>4	>5
Hematocrit decrease	>10%	>10%
BUN increase (mmol/L)	>5	>2
Pao ₂ (mm Hg)	<60	—
Sequestration of fluids (L)	>6	>4
Serum calcium (mg/dL)	<8	<8

Abbreviations: AST, aspartate aminotransferase; BUN, blood urea nitrogen; LDH, lactate dehydrogenase; Pao₂, partial pressure of arterial oxygen.

Data from Refs. ^{14,54,55}

Box 1
APACHE-II parameters
Age
History of organ insufficiency
History of immunocompromise
Rectal temperature
Mean arterial temperature
Heart rate
Respiratory rate
Oxygenation
Serum sodium
Serum potassium
Serum creatinine
Hematocrit
Arterial pH
White blood count

presence and persistence of organ failure. The revised Atlanta Classification was proposed to facilitate communication between clinicians and to serve as an index of severity based on an understanding of the disease process.⁶² This classification takes into account the difference in mortality between transient and persistent organ failure, which is an important distinction because organ failure of less than 48 hours is associated with low mortality, whereas organ failure of more than 48 hours has a predicted mortality of 36%.⁶³

Balthazar and colleagues⁶⁴ introduced the CT severity index (CTSI) that grades severity of acute pancreatitis based on morphologic features including gland enlargement, peripancreatic inflammation, fluid collections, retroperitoneal gas, and degree of pancreatic necrosis, with prognostic implications (**Table 2**). Whereas clinical scores, such as Ranson, APACHE-II, and Glasgow, may have more utility in predicting

Table 2			
Balthazar CT severity index and prognosis			
Grade and CT Findings	Score	Mortality (%)	Degree of Necrosis (%)
A: Normal pancreas	0	3	None
B: Focal or diffuse pancreatic enlargement	1		None
C: Pancreatic/peripancreatic inflammation	2	6	<33
D: Single pancreatic/peripancreatic fluid collection	3		33–50
E: Multiple fluid collections/ retroperitoneal gas	4	17	>50

Data from Balthazar EJ, Ranson JH, Naidich DP, et al. Acute pancreatitis: prognostic value of CT. *Radiology* 1985;156:767–72; and Balthazar EJ, Robinson DL, Megibow AJ, et al. Acute pancreatitis: value of CT in establishing prognosis. *Radiology* 1990;174(2):331–6.

the course of disease early, the CTSI may be more helpful in managing patients with established disease and determining the appropriate future, as opposed to immediate, care.⁶⁵

Other predictors of severity of interest include biochemical markers. C-reactive protein has been shown to correlate with severe disease, and has been advocated as a useful single biochemical marker.⁶⁶ Other potential serum levels such as those of interleukin-6 and macrophage migration inhibitory factor have been evaluated, and further investigation may help incorporate these parameters into novel indices to predict clinical severity.

There are no perfect or universally accepted scoring methods to predict the severity of GSP, particularly early in the disease when the clinician must decide between ICU monitoring or whether to proceed with cholecystectomy. Among all patients with predicted mild pancreatitis, as many as 15% progress to severe disease.^{57,66} It is therefore incumbent on clinicians who choose to use these indices to do so selectively in combination with clinical acumen to determine the best course of management. Regardless of the method, it serves the clinician and patient well to stratify GSP as mild, moderate, or severe.

Initial Management

The general guidelines in managing acute pancreatitis apply equally to GSP. The basis of supportive care is to provide pain control, correct metabolic derangements, aggressively resuscitate with intravenous fluids, and prevent hypoxemia. Patients with an ileus may require a nasogastric tube for decompression. Those with severe disease are best served by a multidisciplinary team approach in the ICU, including gastroenterologists with ERCP capabilities, surgeons comfortable with hepatobiliary surgery, physicians with experience in critical care, and interventional radiologists. Patients with mild disease may require only adequate hydration and pain control before early cholecystectomy.

Nutrition

Patients admitted with acute pancreatitis are typically kept nil by mouth initially. However, those with mild disease benefit from a shorter length of stay in hospital with immediate oral feeding.⁶⁷ GSP patients are no exception, unless early feeding interferes with early cholecystectomy. Patients with severe disease have been shown to benefit from enteral feeding within 48 hours, without exacerbation of illness. Total parenteral nutrition is less safe, less effective, and more expensive, and should be reserved for patients who cannot tolerate enteral feeding. Jejunal feeding is preferred, but gastric feeding has also been shown to be safe.⁶⁸

Antibiotics

Appropriate broad-spectrum antibiotics are indicated pending a workup for sepsis and in infected pancreatic necrosis. In sterile pancreatic necrosis, the use of prophylactic antibiotics is controversial. There are several large studies that disagree as to whether prophylactic antibiotics impart a benefit in pancreatic sepsis and mortality, and recent literature does not recommend antibiotic use in sterile necrosis.⁶⁹⁻⁷¹ It has been shown that prolonged use of broad-spectrum antibiotics increases the risk of developing a fungal infection, so judicious use is imperative.¹⁵

Interventions

Unlike alcoholic acute pancreatitis, whereby the management is primarily to provide supportive care, the management of GSP includes several modalities that are specific

to the disease's underlying cause. These measures include cholecystectomy, exploration of the CBD, ERCP with sphincterotomy, and specific interventional radiology procedures. The goals of these procedures range from mitigating disease severity to preventing the recurrence of GSP.

Cholecystectomy

The goal of cholecystectomy is to prevent recurrence of GSP by removing the source of secondary gallstones. Although 1% to 2% of patients may recur even after cholecystectomy, the rate of recurrence in untreated patients with GSP is up to two-thirds of patients within 3 months of index presentation.^{72–75} Recurrent GSP may be graver than the initial presentation, as between 4% and 50% of cases are reported as severe, and mortality and morbidity is reported in up to 10% and 40%, respectively.^{13,76,77}

Stratifying patients as mild, moderate, or severe has a profound impact on surgical management. Historically, the recommendation was to delay cholecystectomy for 6 to 8 weeks after an attack of acute pancreatitis to allow the inflammation to subside.⁷⁸ High readmission rates for patients waiting for cholecystectomy lead to new guidelines. Although several early studies showed lower morbidity and mortality in delayed operations, the data from some of these studies is interpreted irrespective of patient stratification.^{11,78} Early cholecystectomy in GSP has now been advocated in mild disease for several decades, but what defines early timing, and the challenge of stratifying patients, have led to a great deal of discussion.

Published recommendations and references to early cholecystectomy in mild pancreatitis range from within 48 hours to within 2 to 4 weeks of presentation.^{11,58,72,79,80} Most surgical literature, however, advocates cholecystectomy during the same hospital admission. Whereas many surgeons wait for resolution of abdominal pain and normalization of pancreatic enzymes, Aboulian and colleagues⁸¹ found that laparoscopic cholecystectomy performed within 48 hours of admission for mild pancreatitis, regardless of pain or laboratory values, results in a shorter length of stay in hospital without compromising patient safety or unjustifiably challenging the surgeon's technical ability.⁸² Several other studies support performing laparoscopic cholecystectomy within 48 hours of admission in mild cases, and many others advocate early cholecystectomy within the same hospital admission.^{83,84} It is common practice for surgeons to wait for laboratory values to normalize. However, there are data demonstrating a shorter length of stay in hospital without increased morbidity when surgery is undertaken as laboratory values begin to trend toward normal.⁸⁵ Waiting for complete normalization of pancreatic enzymes may cause a delay in care and an increased length of stay.

There are compelling reasons to recommend cholecystectomy following idiopathic acute pancreatitis, as many patients may have undocumented biliary sludge or microlithiasis. This view is supported by evidence that biliary sludge and microlithiasis are also responsible for the pathologic process cited in GSP.^{86,87} Thus, for the purposes of this review, all acute pancreatitis caused by gallstones, microlithiasis, and biliary sludge is termed GSP.

Despite the compelling data to support early cholecystectomy, compliance is poor and many patients are discharged for interval cholecystectomy. In the Western world, the rate of index cholecystectomy for appropriate surgical candidates is between 10% and 60%.^{88–94} Factors associated with patients who do not undergo early cholecystectomy in the United States include old age, black race, admission to a nonsurgical service, comorbid conditions, and lack of a surgical consultation.⁹⁴ Access to appropriate medical care in certain populations may play a role.⁹⁵ Surveys of surgeons who do not perform early cholecystectomy cite reasons such as busy operating rooms,

budgetary concerns, lack of resources, and concern for a more difficult dissection.^{90,96} Contrary to these concerns, the feasibility of cholecystectomy during index admission, and at most within 2 weeks, has been studied and found to be cost neutral and practical.⁹⁷ In addition, the surgeons involved in one cohort study reported the dissection more difficult during delayed, as opposed to early, laparoscopic cholecystectomy.⁹⁸ Of note is a study with atypical findings from a busy public hospital. Clarke and colleagues⁹⁹ reported that performing index cholecystectomies put an undue strain on hospital resources, and the length of stay was in fact higher in inpatients waiting for index cholecystectomy than in patients directed toward discharge and elective surgical admission. The morbidity was the same in both groups, but 6.5% of patients in the interval laparoscopic cholecystectomy group had unplanned readmissions for mild recurrent pancreatitis.

Severe GSP is associated with significantly higher morbidity and mortality, and the disease process is such that the surgical management follows a more conservative course. Much of the morbidity and mortality reported in early studies that cautioned against early cholecystectomy is attributable to patients with severe forms of GSP. In one such study, Ranson¹⁴ excluded patients with mild pancreatic edema and only considered patients who underwent surgery with pancreatic inflammation in addition to fat necrosis or pancreatic hemorrhage, and reported high mortality. Other studies have reported similar findings whereby high rates of morbidity and mortality in patients undergoing early cholecystectomy were attributable to those patients with moderate and severe disease.¹⁰⁰

Once a patient is stratified as having moderate or severe GSP, the initial management is supportive care and management of complications. Follow-up care includes interval cholecystectomy, delayed at least 3 weeks after resolution, if clinical circumstances permit. Early cholecystectomy is contraindicated in moderate and severe GSP, and is associated with increased infectious complications and sepsis.¹⁰¹

Peripancreatic fluid collections are well recognized on CT and, when correlated to GSP severity, should dramatically influence management.^{64,102} Nealon and colleagues¹⁰³ reported that among patients with moderate to severe GSP who underwent early cholecystectomy, regardless of CT-proven peripancreatic fluid collections, 63% required reoperation and 44% had postoperative complications. Most of the reoperations were for definitive management of pseudocysts, and the infectious complications were presumably a result of pseudocysts that were sterile but became infected at the time of early cholecystectomy. These investigators thus advocate delaying cholecystectomy until it is possible to operatively manage the gallbladder and pseudocysts simultaneously. By virtue of exclusion, almost all investigators advocating early cholecystectomy specify patients with mild disease, and caution against operating too early on those with moderate or severe GSP.

Pseudocysts occur in acute pancreatitis as a result of disruption of the pancreatic duct and extravasated pancreatic excretory fluid. A fluid collection may or may not communicate with the pancreatic duct, and a fibrous wall ultimately forms around the collection (Fig. 4). Pseudocysts may be adequately diagnosed with contrast CT or MRI. A general rule is to wait 6 weeks before intervening to allow the pseudocyst wall to mature.^{103,104} Exceptions to this are cases of infected or symptomatic pseudocysts, when earlier intervention may be indicated. However, there are no universally accepted guidelines for post-GSP pseudocyst management, and a complete discussion of pseudocyst management is beyond the scope of this article. In general, the management is conservative because many of these pseudocysts will resolve spontaneously, especially if there is no patency between the pseudocyst and the pancreatic duct. Because GSP patients with peripancreatic fluid collections or




Fig. 4. Well-circumscribed pseudocyst in the pancreatic head (*arrow*) causing mechanical obstruction of the CBD.

pseudocysts are often discharged for interval cholecystectomy, appropriate follow-up is critical.

Interventional management of pseudocysts with mature walls most commonly includes gastric or proximal enteric drainage by open or endoscopic techniques. Several studies have demonstrated comparable pseudocyst resolution rates in both techniques, and the endoscopic method is favored in simple pseudocysts accessible from the gastric or duodenal lumens.^{105–110} Surgical internal drainage may be indicated in complex pseudocysts and in those not readily accessible endoscopically. The use of EUS may enhance visualization and make otherwise inaccessible pseudocysts manageable with endoscopic drainage.^{105,111} Percutaneous drainage has a role in infected pseudocysts and in symptomatic cases where endoscopic and surgical options are limited. However, this technique risks creating a controlled pancreaticocutaneous fistula, which may persist for an extended period.^{108,112}

Cholecystostomy

In high-risk patients it may be necessary to resort to other means of decompressing the biliary system. Elderly, comorbid, and/or severely ill patients may be deemed unsuitable candidates for either surgery or ERCP, yet still require emergent management of obstructing common duct stones causing biliary sepsis or aggravating acute pancreatitis. In these patients, interventional radiologists may perform percutaneous cholecystostomy, often through the use of ultrasonography and fluoroscopy. This procedure uses the Seldinger technique, and is a minimally invasive method of decompressing the biliary system. However, patients who require this degree of interventional minimalism tend to have a poor prognosis, and 30-day mortality has been reported to be as high as 15.4% in patients undergoing percutaneous cholecystostomy for acute cholecystitis.¹¹³

Intraoperative cholangiography

The role of intraoperative cholangiography (IOC) in GSP is controversial, and its use varies widely among surgeons.¹¹⁴ Some surgeons perform IOC routinely, whereas others do so only when there is a high suspicion for a common duct stone (**Fig. 5**). Although IOC is reported to be 94% specific and 98% sensitive for biliary stones, one study has demonstrated that air bubbles in the ducts can mimic stones in appearance, and routine use may be associated with a substantial false-positive rate.¹¹⁵ Many surgeons will perform an IOC if there is indirect evidence of choledocholithiasis, such as an obstructive pattern on LFTs or a relatively large common duct on




Fig. 5. Intraoperative cholangiogram demonstrating an irregular lucency in the CBD (arrow), representing a stone.

ultrasonography. The diagnosis of GSP should be considered poor indirect evidence of a duct stone, as most stones causing acute pancreatitis pass into the duodenum spontaneously. Nevertheless, the diagnosis of GSP is associated with an increased use of IOC.¹¹⁴ Johnson and Walsh¹¹⁶ found that patients with GSP who undergo IOC during cholecystectomy were more likely to have postoperative ERCP or CBD exploration during surgery, but without influencing the outcome of the pancreatitis. These findings are supported in the literature, as a recent systematic review of IOC use did not identify sufficient evidence to demonstrate a benefit.¹¹⁷ This issue is controversial and requires further investigation.

Laparoscopic exploration of common bile duct

Gallstones passing into the common duct are the offending agents in GSP, and although most pass spontaneously into the duodenum without incident, 7% to 28% of the time stones may remain in the common duct.^{21,118–121} Given sufficient evidence for choledocholithiasis coexistent with mild pancreatitis, it is safe and effective to remove the stone at the time of cholecystectomy by laparoscopic CBD exploration (LCBDE).¹²² Impacted stones causing cholangitis or aggravating severe GSP are generally removed emergently by ERCP, discussed in the next section.

LCBDE has been used for more than 2 decades, and the technology available to safely and effectively perform the procedure has evolved substantially, helping to make it as effective as ERCP in some hands.^{123–125} However, owing to the risks involved in manipulating the CBD and the exceptional level of skill required, most surgeons do not perform this procedure. LCBDE is most commonly performed by surgeons with additional hepatobiliary or laparoscopic training.

Transcystic and transcholedochal approaches are possible laparoscopically. The transcystic method is the favored approach among most surgeons performing LCBDE, and is most suitable for small stones in a small common duct. Choledochotomy is reported to be better for larger, multiple stones in a dilated common duct. Although technically more challenging, LCBDE by choledochotomy may be a more definitive approach.^{116,123,126} Refer to the article by Hardacre and colleagues, elsewhere in this issue for a detailed description of bile duct exploration.

The success of stone clearance by LCBDE has been reported in several studies to be equivalent to ERCP, with decreased morbidity, lower cost, and shorter length of stay.^{127–131} When LCBDE is not an option and patients are either diagnosed with or suspected of having common duct stones, ERCP is favored, in most cases, over open CBD exploration.

Endoscopic retrograde cholangiopancreatography

ERCP refers to the contrast imaging of the biliary and pancreatic ducts (cholangiopancreatography) using a side-viewing endoscope and fluoroscopy. When the ampulla of Vater is accessed in this manner and the CBD cannulated with a guide wire, an endoscopist may then perform endoscopic sphincterotomy or balloon dilatation of the biliary sphincter followed by extraction of stones using a balloon or basket for stones that do not pass spontaneously (**Fig. 6**). For particularly large stones, there are devices available to perform intraluminal lithotripsy to assist in extraction. For diagnostic purposes, the sensitivity of ERCP for choledocholithiasis is 90% to 97%, with 95% to 100% specificity.¹³² This diagnostic performance is similar to that of MRCP, which is noninvasive. The success rate of ERCP in extracting stones is around 95%.

ERCP has been available for more than 30 years, and has largely replaced surgical CBD exploration in cases of isolated choledocholithiasis. The role of ERCP in GSP has been discussed extensively, and it is widely accepted that in mild cases of GSP without evidence of biliary obstruction or cholestasis there is no utility for ERCP for diagnostic or therapeutic purposes.^{133–135} Most patients presenting with transiently elevated pancreatic enzymes without a sustained elevation of bilirubin may proceed to early cholecystectomy without either preoperative or postoperative ERCP. Although earlier reports advocated ERCP within 24 hours for all-comers with GSP, this strategy has been formidably challenged.¹³⁶ There is now widely accepted evidence that ERCP in patients with GSP, but without cholestasis or cholangitis, confers no benefit in terms of complications or mortality.^{137,138}

In patients with severe GSP and evidence of choledocholithiasis, including increasing LFTs, persistently elevated bilirubin, persistent pain, or visualization on




Fig. 6. Fluoroscopic image of endoscopic retrograde cholangiopancreatography during balloon extraction of a large stone.

MRCP, performing ERCP within 72 hours decreases the rate of sepsis, mortality, and complications, including pancreatic necrosis.^{134,139–142} In all patients with GSP, additional evidence of common duct stones warranting intervention includes bile-free gastric aspirate and an increasing level of serial bilirubin. Performing ERCP within 48 hours in these patients may decrease morbidity.¹⁴³ Acute cholangitis may complicate GSP in up to 10% of cases, and early ERCP is indicated to decompress the biliary system in these patients.⁵⁸

ERCP serves a role in mild GSP in patients who are unfit or unwilling to undergo surgery. Although it is well established that patients with GSP have a high rate of recurrence without cholecystectomy, ERCP with sphincterotomy is protective against recurrence of acute pancreatitis. However, because the gallbladder is left in situ, the rates of acute cholecystitis and biliary colic remain elevated.^{2,72,144,145} ERCP is thus indicated in patients with GSP who cannot undergo cholecystectomy, or will experience a prolonged delay before cholecystectomy.

Complications of ERCP include pancreatitis, hemorrhage, perforation, cholangitis, and stenosis of the sphincter of Oddi.^{127,146} Although an increased risk of cholangiocarcinoma after ERCP has been discussed in the literature, there is currently insufficient evidence to confirm this concern.

Special patient populations

As the incidence of GSP increases in the adult population, a similar increase in gallstone disease is being observed in the pediatric population. The recommendation for index-admission cholecystectomy prevails in children with mild GSP, as in adults.^{147,148}

Pregnancy is a risk factor for gallstone formation, and as many as one-third of pregnant patients presenting with biliary complaints require surgical intervention.^{149–151} Gallstone disease underlies 65% to 70% of cases of acute pancreatitis occurring during pregnancy.¹⁵² Previous recommendations warned against performing laparoscopy on pregnant patients during the first trimester, and cited limitations of intra-abdominal visualization caused by the third-trimester uterus. Thus pregnant patients presenting during the first and third trimester underwent delayed cholecystectomy. However, guidelines within the last decade endorsed by the Society of American Gastrointestinal and Endoscopic Surgeons cite substantial evidence in support of safely performing laparoscopic procedures during any trimester of pregnancy. The recommendations additionally state that the indications for laparoscopic cholecystectomy for biliary disease should also be honored in pregnancy.¹⁵³ Delaying cholecystectomy in pregnant patients carries a formidable risk of recurrent GSP, for both the patient and the fetus, which likely outweighs the poorly quantified risk of spontaneous abortion. EUS or MRCP without gadolinium contrast may be safely used in pregnancy to select pregnant patients for further intervention, including ERCP or LCBDE, if choledocholithiasis is suspected or confirmed.

It is estimated that 30% of patients older than 70 years have gallstones, and the incidence of choledocholithiasis in the elderly population is up to 20%.^{154,155} Because older patients are more likely to have gallstones and bile ducts of increased diameter, this population also has a higher incidence of GSP.¹⁵⁶ Several studies demonstrate the safety of performing laparoscopic cholecystectomy in elderly patients, yet less than 57% of older patients undergo index cholecystectomy, and it is estimated that compliance can be improved to greater than 70% while still maintaining appropriate patient selection.^{94,157,158} Recurrent GSP should be prevented in the young and elderly populations with index cholecystectomy in mild GSP, when clinically feasible.

SUMMARY

GSP is a disease with a wide spectrum of severity. Diagnosis and management have evolved over the past several decades with the advent of new and improved technology. Advancements in imaging techniques have limited the need for invasive diagnostic procedures in many cases, and diverse therapeutic options are becoming more widely available. The paradigm continues to shift toward earlier operation in mild cases, with more judicious interventions in severe disease. Risk stratification is essential to provide the best possible care for all patients, and good clinical judgment is paramount in selecting the most pertinent invasive and diagnostic procedures at the most appropriate time.

REFERENCES

1. Whitcomb DC. Acute pancreatitis. *N Engl J Med* 2006;354(20):2142–50.
2. Ito K, Ito H, Whang EE. Timing of cholecystectomy for biliary pancreatitis: do the data support current guidelines? *J Gastrointest Surg* 2008;12(12):2164–70.
3. Frossart JL, Steer ML, Pastor CM. Acute pancreatitis. *Lancet* 2008;372(9607):143–52.
4. Baillie J. Treatment of acute biliary pancreatitis. *N Engl J Med* 1997;336(4):286–7.
5. Yadav D, Lowenfels AB. Trends in the epidemiology of the first attack of acute pancreatitis: a systematic review. *Pancreas* 2006;33(4):323–30.
6. Steinberg W, Tenner S. Acute pancreatitis. *N Engl J Med* 1994;330(17):1198–210.
7. Cappell MS. Acute pancreatitis: etiology, clinical presentation, diagnosis, and therapy. *Med Clin North Am* 2008;92(4):889–923.
8. Fagenholz PJ, Fernandez-del CC, Harris NS, et al. Direct medical costs of acute pancreatitis hospitalizations in the United States. *Pancreas* 2007;35:302–7.
9. Sandler RS, Ecerhart JE, Donowitz M, et al. The burden of selective digestive diseases in the United States. *Gastroenterol* 2002;122:1500–11.
10. Attasaranya S, Fogel EL, Lehman GA. Choledocholithiasis, ascending cholangitis, and gallstone pancreatitis. *Med Clin North Am* 2008;92(4):925–60.
11. Uhl W, Müller CA, Krähenbühl L, et al. Acute gallstone pancreatitis: timing of laparoscopic cholecystectomy in mild and severe disease. *Surg Endosc* 1999;13(11):1070–6.
12. Armstrong CP, Taylor TV, Torrance HB. Effects of bile, infection, and pressure on pancreatic duct integrity. *Br J Surg* 1985;72:792–5.
13. Moreau JA, Zinsmeister AR, Melton LJ 3rd, et al. Gallstone pancreatitis and the effect of cholecystectomy: a population based cohort study. *Mayo Clin Proc* 1988;63:466–73.
14. Ranson JH. The timing of biliary surgery in acute pancreatitis. *Ann Surg* 1979;189:654–63.
15. Banks PA, Freeman ML. Practice guidelines in acute pancreatitis. *Am J Gastroenterol* 2006;101(10):2379–400.
16. Diehl AK. Epidemiology and natural history of gallstone disease. *Gastroenterol Clin North Am* 1991;20:11–9.
17. Friedman GD. Natural history of asymptomatic and symptomatic gallstones. *Am J Surg* 1993;165:399–404.
18. Portincases P, Moschetta A, Palasciano G. Cholesterol gallstone disease. *Lancet* 2006;368:230–9.

19. Ko CE, Lee SP. Epidemiology and natural history of common bile duct stones and prediction of diseases. *Gastrointest Endosc* 2002;56(Suppl 6):S165–9.
20. Prince M. Pancreatic apoplexy with a report of two cases. *Boston Med Surg J* 1882;107:28–32.
21. Raraty MG, Finch M, Neoptolemos JP. Acute cholangitis and pancreatitis secondary to common duct stones: management update. *World J Surg* 1998; 22(11):1155–61.
22. Opie EL. The aetiology of acute haemorrhagic pancreatitis. *Bull Johns Hopkins Hosp* 1901;12:182.
23. Venneman NG, Buskens E, Besselink MG, et al. Small gallstones are associated with increased risk of acute pancreatitis: potential benefits of prophylactic cholecystectomy? *Am J Gastroenterol* 2005;100:2540–50.
24. Sugiyama M, Atomi Y. Risk factors for acute biliary pancreatitis. *Gastrointest Endosc* 2004;60:210–2.
25. Diehl AK, Holleman DR Jr, Chapman JB, et al. Gallstone size and risk of pancreatitis. *Arch Intern Med* 1997;157:1674–8.
26. Lerch M, Aghdassi A. The role of bile acids in gallstone-induced pancreatitis. *Gastroenterol* 2010;138(2):426–9.
27. Muili KA, Wang D, Orabi AI, et al. Bile acids induce pancreatic acinar cell injury and pancreatitis by activating calcineurin. *J Biol Chem* 2012;288(1):570–80.
28. Acosta JM, Pellegrini CA, Skinner DB. Etiology and pathogenesis of acute biliary pancreatitis. *Surgery* 1980;88:118–25.
29. Hirano T, Manabe T. A possible mechanism for gallstone pancreatitis: repeated short-term pancreaticobiliary duct obstruction with exocrine stimulation in rats. *Proc Soc Exp Biol Med* 1993;202:246–52.
30. Yadav D, Papachristou GI, Whitcomb DC. Alcohol-associated pancreatitis. *Gastroenterol Clin North Am* 2007;36(2):219–38.
31. Zieve L. Clinical value of determinations of various pancreatic enzymes in serum. *Gastroenterol* 1964;46:62–7.
32. Wang SS, Lin XZ, Tsai YT, et al. Clinical significance of ultrasonography, computed tomography, and biochemical tests in the rapid diagnosis of gallstone-related pancreatitis: a prospective study. *Pancreas* 1988;3:153–8.
33. Fogel EL, Sherman S. Acute biliary pancreatitis: when should the endoscopist intervene? *Gastroenterol* 2003;125:229–35.
34. Nathwani RA, Kumar SR, Reynolds TB, et al. Marked elevation in serum transaminases: an atypical presentation of choledocholithiasis. *Am J Gastroenterol* 2005;100:295–8.
35. Dholakia K, Pitchumoni CS, Agarwal N. How often are liver function tests normal in acute biliary pancreatitis? *J Clin Gastroenterol* 2004;38:81–3.
36. Tenner S, Dubner H, Steinberg W. Predicting gallstone pancreatitis with laboratory parameters: a meta-analysis. *Am J Gastroenterol* 1994;89:1863–6.
37. Neoptolemos JP, Hall AW, Finlay DF, et al. The urgent diagnosis of gallstones in acute pancreatitis: a prospective study of three methods. *Br J Surg* 1984;71:230–3.
38. Sugiyama M, Atomi Y. Endoscopic ultrasonography for diagnosing choledocholithiasis: a prospective comparative study with ultrasonography and computed tomography. *Gastrointest Endosc* 1997;45:143–6.
39. Amouyal P, Amouyal G, Levy P, et al. Diagnosis of choledocholithiasis by endoscopic ultrasonography. *Gastroenterol* 1994;106:1062–7.
40. O'Connor HJ, Hamilton I, Ellis WR, et al. Ultrasound detection of choledocholithiasis: prospective comparison with ERCP in the postcholecystectomy patient. *Gastrointest Radiol* 1986;11(2):161–4.

41. Thorboll J, Vilmann P, Jacobsen B, et al. Endoscopic ultrasonography in detection of cholelithiasis in patients with biliary pain and negative transabdominal ultrasonography. *Scand J Gastroenterol* 2004;39:267–9.
42. Balthazar EJ, Ranson JH, Naidich DP, et al. Acute pancreatitis: prognostic value of CT. *Radiology* 1985;156:767–72.
43. Polkowski M, Palucki J, Regula J, et al. Helical computed tomographic cholangiography versus endosonography for suspected bile duct stones: a prospective blinded study in non-jaundiced patients. *Gut* 1999;45:744–9.
44. Cabada Giadas T, Sarria Octavio de Toledo L, Martinez-Berganza Asensio MT, et al. Helical CT cholangiography in the evaluation of the biliary tract: application to the diagnosis of choledocholithiasis. *Abdom Imaging* 2002;27:61–70.
45. Kim HJ, Park DI, Park JH, et al. Multidetector computed tomography cholangiography with multiplanar reformation for the assessment of patients with biliary obstruction. *J Gastroenterol Hepatol* 2007;22:400–5.
46. Balthazar EJ. Acute pancreatitis: assessment of severity with clinical and CT evaluation. *Radiology* 2002;223:603–13.
47. Verma D, Kapadia A, Eisen GM, et al. EUS vs MRCP for detection of choledocholithiasis. *Gastrointest Endosc* 2006;64:248–54.
48. McMahon CJ. The relative roles of magnetic resonance cholangiopancreatography (MRCP) and endoscopic ultrasound in diagnosis of common bile duct calculi: a critically appraised topic. *Abdom Imaging* 2008;33(1):6–9.
49. Hirota M, Kimura Y, Ishiko T, et al. Visualization of the heterogeneous internal structure of so-called “pancreatic necrosis” by magnetic resonance imaging in acute necrotizing pancreatitis. *Pancreas* 2002;25:63–7.
50. Buscarini E, Tansini P, Vallisa D, et al. EUS for suspected choledocholithiasis: do benefits outweigh costs? A prospective, controlled study. *Gastrointest Endosc* 2003;57:510–8.
51. De Lisi S, Leandro G, Buscarini E. Endoscopic ultrasonography versus endoscopic retrograde cholangiopancreatography in acute biliary pancreatitis. *Eur J Gastroenterol Hepatol* 2011;23(5):367–74.
52. Amouyal P, Palazzo L, Amouyal G, et al. Endosonography: promising method for diagnosis of extrahepatic cholestasis. *Lancet* 1989;2:1195–8.
53. Norton SA, Alderson D. Prospective comparison of endoscopic ultrasonography and endoscopic retrograde cholangiopancreatography in the detection of bile duct stones. *Br J Surg* 1997;84:1366–9.
54. Ranson JH, Rifkind KM, Roses DF. Prognostic signs and the role of operative management in acute pancreatitis. *Surg Gynecol Obstet* 1974;139:69–81.
55. Ranson JH. Etiologic and prognostic factors in human acute pancreatitis: a review. *Am J Gastroenterol* 1982;77:633–8.
56. Yeung YP, Kit Lam BY, Chun Yip AW. APACHE system is better than Ranson system in the prediction of severity of acute pancreatitis. *Hepatobiliary Pancreat Dis Int* 2006;5(2):294–9.
57. Papachristou GI, Muddana V, Yadav D, et al. Comparison of BISAP, Ranson's, APACHE-II, and CTSI scores in predicting organ failure, complications, and mortality in acute pancreatitis. *Am J Gastroenterol* 2009;105(2):435–41.
58. Forsmark CE, Baillie J. AGA Institute technical review on acute pancreatitis. *Gastroenterol* 2007;132(5):2022–44.
59. De Bernardinis M, Violi V, Roncoroni L, et al. Discriminant power and information content of Ranson's prognostic signs in acute pancreatitis: a meta-analytic study. *Crit Care Med* 1999;27(10):2272–83.

60. Wilson C, Heath DI, Imrie CW. Prediction of outcome in acute pancreatitis: a comparative study of APACHE-II, clinical assessment and multiple factor scoring systems. *Br J Surg* 1990;77:1260–4.
61. Khan AA, Parekh D, Cho Y, et al. Improved prediction of outcome in patients with severe acute pancreatitis by the APACHE II score at 48 hours after hospital admission compared with APACHE II score at admission. *Arch Surg* 2002;137:1136–40.
62. Banks PA, Bollen TL, Dervenis C, et al. Classification of acute pancreatitis—2012: revision of the Atlanta classification and definitions by international consensus. *Gut* 2013;62(1):102–11.
63. Johnson CD, Abu-Hilal M. Persistent organ failure during the first week as a marker of fatal outcome in acute pancreatitis. *Gut* 2004;53:1340–4.
64. Balthazar EJ, Robinson DL, Megibow AJ, et al. Acute pancreatitis: value of CT in establishing prognosis. *Radiology* 1990;174(2):331–6.
65. Alhajeri A, Erwin S. Acute pancreatitis: value and impact of CT severity index. *Abdom Imaging* 2007;33(1):18–20.
66. Dambrauskas Z, Gulbinas A, Pundzius J, et al. Value of the different prognostic systems and biological markers for predicting severity and progression of acute pancreatitis. *Scand J Gastroenterol* 2010;45(7–8):959–70.
67. Eckerwall GE, Tingstedt BB, Bergenzaun PE, et al. Immediate oral feeding in patients with mild acute pancreatitis is safe and may accelerate recovery—a randomized clinical study. *Clin Nutr* 2007;26(6):758–63.
68. Eatock FC, Chong P, Menezes N, et al. A randomized study of early nasogastric versus nasojejunal feeding in severe acute pancreatitis. *Am J Gastroenterol* 2005;100:432–9.
69. Bassi C, Larvin M, Villatoro E. Antibiotic therapy for prophylaxis against infection of pancreatic necrosis in acute pancreatitis. *Cochrane Database Syst Rev* 2003;(4):CD002941.
70. Isenmann R, Runzi M, Kron M, et al. Prophylactic antibiotic treatment in patients with predicted severe acute pancreatitis: a placebo-controlled, double-blind trial. *Gastroenterol* 2004;126:997–1004.
71. Dellinger EP, Tellado JM, Soto NE, et al. Early antibiotic treatment for severe acute necrotizing pancreatitis: a randomized, double-blind, placebo-controlled study. *Ann Surg* 2007;245:674–83.
72. Van Baal MC, Besselink MG, Bakker OJ, et al. Timing of cholecystectomy after mild biliary pancreatitis: a systematic review. *Ann Surg* 2012;255(5):860–6.
73. Cameron DR, Goodman AJ. Delayed cholecystectomy for gallstone pancreatitis: re-admissions and outcomes. *Ann R Coll Surg Engl* 2004;86:358–62.
74. Nebiker CA, Frey DM, Hamel CT, et al. Early versus delayed cholecystectomy in patients with biliary acute pancreatitis. *Surg* 2009;145:260–4.
75. Delhaye M, Matos C, Deviere J. Endoscopic technique for the management of pancreatitis and its complications. *Best Pract Res Clin Gastroenterol* 2004;18:155–81.
76. Lankisch PG, Bruns A, Doobe C, et al. The second attack of acute pancreatitis is not harmless. *Pancreas* 2008;36:207–8.
77. Hernandez V, Pascual I, Almela P, et al. Recurrence of acute gallstone pancreatitis and relationship with cholecystectomy or endoscopic sphincterotomy. *Am J Gastroenterol* 2004;99:2417–23.
78. Pellegrini CA. Surgery for gallstone pancreatitis. *Am J Surg* 1993;165(4):515–8.
79. Working Party of the British Society of Gastroenterology, Association of Surgeons of Great Britain and Ireland, Pancreatic Society of Great Britain and

- Ireland, et al. UK guidelines for the management of acute pancreatitis. *Gut* 2005;54(Suppl 3):iii1–9.
80. El-Dhuwaib Y, Deakin M, David G, et al. Definitive management of gallstone pancreatitis in England. *Ann R Coll Surg Engl* 2012;94(6):402–6.
 81. Aboulian A, Chan T, Yaghoubian A, et al. Early cholecystectomy safely decreases hospital stay in patients with mild gallstone pancreatitis. *Ann Surg* 2010;251(4):615–9.
 82. Larson SD, Nealon WH, Evers BM. Management of gallstone pancreatitis. *Adv Surg* 2006;40:265–84.
 83. De Virgilio C. Early laparoscopic cholecystectomy for mild gallstone pancreatitis: time for a paradigm shift. *Arch Surg* 2012;147(11):1031–5.
 84. Rosing DK, de Virgilio C, Yaghoubian A, et al. Early cholecystectomy for mild to moderate gallstone pancreatitis shortens hospital stay. *J Am Coll Surg* 2007;205(6):762–6.
 85. Taylor E, Wong C. The optimal timing of laparoscopic cholecystectomy in mild gallstone pancreatitis. *Am Surg* 2004;70(11):971–5.
 86. Lee SP, Nicholls JF, Park HZ. Biliary sludge as a cause of acute pancreatitis. *N Engl J Med* 1992;326:589–93.
 87. Ros E, Navarro S, Bru C, et al. Occult microlithiasis in 'idiopathic' acute pancreatitis: prevention of relapses by cholecystectomy or ursodeoxycholic acid therapy. *Gastroenterol* 1991;101(6):1701–9.
 88. Nguyen GC, Tuskey A, Jagannath SB. Racial disparities in cholecystectomy rates during hospitalizations for acute gallstone pancreatitis: a national survey. *Am J Gastroenterol* 2008;103:2301–7.
 89. Sandzen B, Rosenmuller M, Haapamaki MM, et al. First attack of acute pancreatitis in Sweden 1988–2003: incidence, aetiological classification, procedures and mortality—a register study. *BMC Gastroenterol* 2009;9:18.
 90. Campbell EJ, Montgomery DA, Mackay CJ. A national survey of current surgical treatment of acute gallstone disease. *Surg Laparosc Endosc Percutan Tech* 2008;18:242–7.
 91. Senapati PS, Bhattacharya D, Harinath G, et al. A survey of the timing and approach to the surgical management of cholelithiasis in patients with acute biliary pancreatitis and acute cholecystitis in the UK. *Ann R Coll Surg Engl* 2003;85:306–12.
 92. Chiang DT, Thompson G. Management of acute gallstone pancreatitis: so the story continues. *ANZ J Surg* 2008;78(1–2):52–4.
 93. Sanjay P, Yeeting S, Whigham C, et al. Management guidelines for gallstone pancreatitis. Are the targets achievable? *JOP* 2009;10(1):43–7.
 94. Trust MD, Sheffield KM, Boyd CA, et al. Gallstone pancreatitis in older patients: are we operating enough? *Surg* 2011;150(3):515–25.
 95. Everhart JE. Gallstones and ethnicity in the Americas. *J Assoc Acad Minor Phys* 2001;12(3):137–43.
 96. Lankisch PG, Weber-Dany B, Lerch MM. Clinical perspectives in pancreatology: compliance with acute pancreatitis guidelines in Germany. *Pancreatology* 2005;5:591–3.
 97. Monkhouse SJ, Court EL, Dash I, et al. Two-week target for laparoscopic cholecystectomy following gallstone pancreatitis is achievable and cost neutral. *Br J Surg* 2009;96(7):751–5.
 98. Sinha R. Early laparoscopic cholecystectomy in acute biliary pancreatitis: the optimal choice? *HPB (Oxford)* 2008;10(5):332–5.

99. Clarke T, Sohn H, Kelso R, et al. Planned early discharge-elective surgical readmission pathway for patients with gallstone pancreatitis. *Arch Surg* 2008; 143(9):901.
100. Kelly TR, Wagner DS. Gallstone pancreatitis: a prospective randomized trial of the timing of surgery. *Surg* 1988;104:600–3.
101. Delorio AV Jr, Vitale GC, Reynolds M, et al. Acute biliary pancreatitis. The roles of laparoscopic cholecystectomy and endoscopic retrograde cholangiopancreatography. *Surg Endosc* 1995;9:392–6.
102. Brun A, Agarwal N, Pitchumoni CS. Fluid collections in and around the pancreas in acute pancreatitis. *J Clin Gastroenterol* 2011;45(7):614–25.
103. Nealon WH, Bawduniak J, Walser EM. Appropriate timing of cholecystectomy in patients who present with moderate to severe gallstone-associated acute pancreatitis with peripancreatic fluid collections. *Ann Surg* 2004;239(6): 741–51.
104. Martin RF, Hein AR. Operative management of acute pancreatitis. *Surg Clin North Am* 2013;93(3):595–610.
105. Johnson MD, Walsh RM, Henderson JM, et al. Surgical versus nonsurgical management of pancreatic pseudocysts. *J Clin Gastroenterol* 2009;43(6):586–90.
106. Beckingham IJ, Krige JEJ, Bornam PC, et al. Endoscopic management of pancreatic pseudocysts. *Br J Surg* 1997;84:1638–45.
107. Gumaste VV, Dave PB. Editorial: pancreatic pseudocyst—the needle or the scalpel? *J Clin Gastroenterol* 1991;13:500–5.
108. Samuelson AL, Shah RJ. Endoscopic management of pancreatic pseudocysts. *Gastroenterol Clin North Am* 2012;41(1):47–62.
109. Varadarajulu S, Lopes TL, Wilcox CM, et al. EUS versus surgical cystgastrostomy for management of pancreatic pseudocysts. *Gastrointest Endosc* 2008;68:649–55.
110. Melman L, Azar R, Beddow K, et al. Primary and overall success rates for clinical outcomes after laparoscopic, endoscopic, and open pancreatic cystgastrostomy for pancreatic pseudocysts. *Surg Endosc* 2009;23:267–71.
111. Kruger M, Schneider AS, Manns MP, et al. Endoscopic management of pseudocysts or abscesses after an EUS-guided 1-step procedure for initial access. *Gastrointest Endosc* 2006;63:409–16.
112. Adams DB, Anderson MC. Percutaneous catheter drainage compared with internal drainage in the management of pancreatic pseudocyst. *Ann Surg* 1992; 215:571–8.
113. Winbladh A, Gullstrand P, Svanvik J, et al. Systematic review of cholecystostomy as a treatment option in acute cholecystitis. *HPB* 2009;11(3):183–93.
114. Sheffield KM, Han Y, Kuo YF, et al. Variation in the use of intraoperative cholangiography during cholecystectomy. *J Am Coll Surg* 2012;214(4):668–79.
115. Griniatsos J, Karvounis E, Isla AM. Limitations of fluoroscopic intraoperative cholangiography in cases suggestive of choledocholithiasis. *J Laparoendosc Adv Surg Tech A* 2005;15:312–7.
116. Johnson PM, Walsh MJ. The impact of intraoperative cholangiography on recurrent pancreatitis and biliary complications in patients with gallstone pancreatitis. *J Gastrointest Surg* 2012;16(12):2220–4.
117. Ford JA, Soop M, Du J, et al. Systematic review of intraoperative cholangiography in cholecystectomy. *Br J Surg* 2012;99(2):160–7.
118. Tabone LE, Conlon M, Fernando E, et al. A practical cost-effective management strategy for gallstone pancreatitis. *Am J Surg* 2013;206(4):472–7.

119. Frossard JL, Hadengue A, Amouyal G, et al. Choledocholithiasis: a prospective study of spontaneous common bile duct stone migration. *Gastrointest Endosc* 2000;51(2):175–9.
120. Bennion RS, Wyatt LE, Thompson JE. Effect of intra-operative cholangiography during cholecystectomy on outcome after gallstone pancreatitis. *J Gastrointest Surg* 2002;6:575–81.
121. Ito K, Ito H, Tavakkolizadeh A, et al. Is ductal decompression always necessary before or during surgery for biliary pancreatitis? *Am J Surg* 2008;195:463–6.
122. Grubnik VV, Tkachenko AI, Ilyashenko VV, et al. Laparoscopic common bile duct exploration versus open surgery: comparative prospective randomized trial. *Surg Endosc* 2012;26(8):2165–71.
123. Koc B, Karahan S, Adas G, et al. Comparison of laparoscopic common bile duct exploration and endoscopic retrograde cholangiopancreatography plus laparoscopic cholecystectomy for choledocholithiasis: a prospective randomized study. *Am J Surg* 2013;206(4):457–63.
124. Jacobs M, Verdeja JC, Goldstein HS. Laparoscopic choledocholithotomy. *J Laparoendosc Surg* 1991;1:79–82.
125. Petelin J. Laparoscopic approach to common duct pathology. *Surg Laparosc Endosc* 1991;1:33–41.
126. Tokamura H, Umezawa A, Cao H, et al. Laparoscopic management of common bile duct stones: transcystic approach and choledochotomy. *J Hepatobiliary Pancreat Surg* 2002;9:206–12.
127. Rogers SJ, Cello JP, Horn JK, et al. Prospective randomized trial of LC + LCBDE vs ERCP/S + LC for common bile duct stone disease. *Arch Surg* 2010;145(1):28.
128. Sgourakis G, Karaliotas K. Laparoscopic common bile duct exploration and cholecystectomy versus endoscopic stone extraction and laparoscopic cholecystectomy for choledocholithiasis: a prospective randomized study. *Minerva Chir* 2002;57(4):467–74.
129. Paganini AM, Lezoche E. Follow-up of 161 unselected consecutive patients treated laparoscopically for common bile duct stones. *Surg Endosc* 1998;12:23–9.
130. Guruswamy KS, Samaraj K. Primer closure versus T-tube drainage after laparoscopic common bile duct exploration. *Cochrane Database Syst Rev* 2007;(1):CD005641.
131. Ebner S, Rechner J, Beller S. Laparoscopic management of common bile duct stones. *Surg Endosc* 2004;18:762–76.
132. Frey CF, Burbige EJ, Meinke WB, et al. Endoscopic retrograde cholangiopancreatography. *Am J Surg* 1982;144:109–14.
133. Moretti A, Papi C, Aratari A, et al. Is early endoscopic retrograde cholangiopancreatography useful in the management of acute biliary pancreatitis? *Dig Liver Dis* 2008;40(5):379–85.
134. Tse F, Yuan Y. Early routine endoscopic retrograde cholangiopancreatography strategy versus early conservative management strategy in acute gallstone pancreatitis. *Cochrane Database Syst Rev* 2012;(5):CD009779.
135. Van Santvoort HC, Besselink MG, de Vries AC, et al. Early endoscopic retrograde cholangiopancreatography in predicted severe acute biliary pancreatitis. *Ann Surg* 2009;250(1):68–75.
136. Fan ST, Lai E, Mok F, et al. Early treatment of acute biliary pancreatitis by endoscopic papillotomy. *N Engl J Med* 1993;328(4):228–32.

137. Cohen S, Bacon BR, Berlin JA. National Institutes of Health State-of-the-Sciences conference statement: ERCP for diagnosis and therapy. *Gastrointest Endosc* 2002;56(6):803–9.
138. Petrov MS, van Santvoort HC, Besselink MG, et al. Early endoscopic retrograde cholangiopancreatography versus conservative management in acute biliary pancreatitis without cholangitis: a meta-analysis of randomized trials. *Ann Surg* 2008;247(2):250–7.
139. Berci G, Morgenstern L. Laparoscopic management of common bile duct stones. A multi-institutional SAGES study. *Society of American Gastrointestinal Endoscopic Surgeons. Surg Endosc* 1994;8:1168–74.
140. Neoptolemos JP, Carr-Locke DL, London NJ, et al. Controlled trial of urgent endoscopic retrograde cholangiopancreatography and endoscopic sphincterotomy versus conservative treatment for acute pancreatitis due to gallstones. *Lancet* 1988;2:979–83.
141. Folsch UR, Nitsche R, Ludtke R, et al. Early ERCP and papillotomy compared with conservative treatment for acute biliary pancreatitis. The German Study Group on Acute Biliary Pancreatitis. *N Engl J Med* 1997;336:237–42.
142. Baillie J. Does every patient with gallstone pancreatitis require ERCP? *Curr Gastroenterol Rep* 2008;10(2):147–9.
143. Acosta JM, Katkhouda N, Debian KA, et al. Early ductal decompression versus conservative management for gallstone pancreatitis with ampullary obstruction: a prospective randomized clinical trial. *Ann Surg* 2006;243:33–40.
144. van Geenen EJ, van der Peet DL, Mulder CJ, et al. Recurrent acute biliary pancreatitis: the protective role of cholecystectomy and endoscopic sphincterotomy. *Surg Endosc* 2009;23:950–6.
145. Lau JY, Leow CK, Fung TM, et al. Cholecystectomy or gallbladder in situ after endoscopic sphincterotomy and bile duct stone removal in Chinese patients. *Gastroenterol* 2006;130:96–103.
146. Swanstrom LL, Marcus DR, Kenyon T. Laparoscopic treatment of known choledocholithiasis. *Surg Endosc* 1996;10(5):526–8.
147. Knott EM, Gasior AC, Bikhchandani J, et al. Surgical management of gallstone pancreatitis in children. *J Laparoendosc Adv Surg Tech A* 2012;22(5):501–4.
148. Chang YJ, Chao HC, Kong MS, et al. Acute pancreatitis in children. *Acta Paediatr* 2011;100:740–4.
149. Polydorou A, Karapanos K, Vezakis A, et al. A multimodal approach to acute biliary pancreatitis during pregnancy: a case series. *Surg Laparosc Endosc Percutan Tech* 2012;22(5):429–32.
150. Al-Hashem H, Muralidharan V, Cohen H, et al. Biliary disease in pregnancy with an emphasis on the role of ERCP. *J Clin Gastroenterol* 2009;43(1):58–62.
151. Ko CW, Beresford SA, Schulte SJ, et al. Incidence, natural history, and risk factors for biliary sludge and stones during pregnancy. *Hepatology* 2005;41(2):359–65.
152. Date RS, Kaushal M, Ramesh A. A review of the management of gallstone disease and its complications in pregnancy. *Am J Surg* 2008;196:599–608.
153. Pearl J, Price R, Richardson W, et al. Guidelines for diagnosis, treatment, and use of laparoscopy for surgical problems during pregnancy. *Surg Endosc* 2011;25(11):3479–92.
154. Lee A, Min SK, Park JJ, et al. Laparoscopic common bile duct exploration for elderly patients: as a first treatment strategy for common bile duct stones. *J Korean Surg Soc* 2011;81:128–33.
155. Schirmer BD, Winter KL, Edlich RF. Cholelithiasis and cholecystitis. *J Long Term Eff Med Implants* 2005;15:329–38.

156. Kaim A, Steinke K, Frank M, et al. Diameter of the common bile duct in the elderly patient: measurement by ultrasound. *Eur Radiol* 1998;8:1413–5.
157. Hazzan D, Geron N, Golijanin D, et al. Laparoscopic cholecystectomy in octogenarians. *Surg Endosc* 2003;17(5):773–6.
158. Marcari RS, Lupinacci RM, Nadal LR, et al. Outcomes of laparoscopic cholecystectomy in octogenarians. *JLS* 2012;16(2):271–5.